Do antidepressants like Lexapro raise heart risks?
Not in the early weeks, based on this analysis. Escitalopram (Lexapro) and amitriptyline did lengthen a heart-rhythm measure called the QTc interval, but across 139 trials with 52,398 people, antidepressants were not linked to more early major heart and blood vessel events or non-suicidal deaths than placebo.
The question of antidepressants and heart risk comes up often, and for good reason. Some of these drugs can change the heart’s electrical timing. On a heart tracing (an ECG), the QT interval is the time the heart takes to recharge between beats. Doctors adjust it for heart rate, and that adjusted number is the QTc. A longer QTc is one reason a doctor might pause before choosing a particular drug.
A team from Oxford, Verona, and Southern Denmark, publishing in The BMJ, set out to answer two things. First, how much does each antidepressant change the QTc in the first eight weeks of treatment? Second, do people starting antidepressants have more serious heart events early on?
What the data show
The researchers found 130 double-blind randomized trials in adults with major depression. Thirty-five of them shared individual-level heart tracing data, covering 8,679 people. These trials tested placebo and 10 antidepressants: amitriptyline, bupropion, duloxetine, escitalopram, fluoxetine, mirtazapine, paroxetine, trazodone, venlafaxine, and vortioxetine.
Compared with placebo, escitalopram lengthened the QTc by about 8.7 milliseconds. The true effect is very likely somewhere between 1.6 and 15.8 milliseconds (95% credibility interval). Amitriptyline lengthened it by about 5.3 milliseconds, very likely between 0.8 and 9.8 milliseconds. Once personal risk factors were taken into account, amitriptyline and escitalopram most often ranked as causing the largest QTc increases. Venlafaxine and vortioxetine most often ranked lowest.
Then came the question that matters most to patients. A broader analysis pooled 139 trials with 52,398 participants. It found no link between antidepressant use and higher rates of early major cardiovascular events (the category that covers problems like heart attacks and strokes) and non-suicidal death compared with placebo. The difference was 0.01%, or about 1 extra event per 10,000 people. The range ran from roughly 1 fewer to 2 more per 10,000 (95% credibility interval -0.01% to 0.02%), so the true difference could easily be zero.
Dr. Kumar’s Take
This is a reassuring study, and it is also a useful one. The heart-rhythm fear around antidepressants has been around for years. Here, the two drugs with measurable QTc changes compared with placebo were escitalopram and amitriptyline. Those shifts are real, but they are measured in milliseconds on an ECG, and the larger analysis found no rise in early major cardiovascular events or non-suicidal sudden death.
The more interesting finding is how much the effect varied from person to person. The authors flagged “important variability,” especially for escitalopram, fluoxetine, and mirtazapine. Their conclusion is that a person’s own risk factors should guide the choice of drug. I agree with that. A healthy 30-year-old and an older adult with kidney disease and a long baseline QTc are not the same patient, even if they have the same diagnosis.
How strong is the evidence?
This analysis has real strengths. Every trial was double-blind and randomized, so neither patients nor researchers knew who got the drug. The QTc analysis used each person’s own data rather than trial averages. That let the team account for baseline QTc, age, sex assigned at birth, body mass index, blood potassium level, and kidney function (estimated glomerular filtration rate). Each of these can shift how the heart responds to a drug.
There are limits too. Only 35 of the 130 trials had individual heart data, so the QTc findings rest on about a quarter of the available research. The window was short, covering early treatment rather than years of use. Clinical trials also tend to enroll healthier volunteers than the people who take these drugs in everyday life. So the results speak most clearly to early treatment in trial-like patients.
Practical Takeaways
- If you take escitalopram or amitriptyline, this study found a small QTc increase but no rise in early major cardiovascular events, so do not stop your medicine on your own.
- If you have a heart rhythm problem, low potassium, or reduced kidney function, ask your doctor whether an ECG makes sense before or after starting an antidepressant.
- Tell your doctor about your age, kidney function, and any past ECG results, since the researchers say these kinds of personal risk factors should shape which antidepressant fits you best.
Related Studies and Research
- 21 antidepressants compared: which work best for depression?
- Single-dose psilocybin vs placebo: first double-blind depression trial
- Mindfulness-based cognitive therapy prevents depression relapse: individual patient meta-analysis
- Chronic L-theanine for major depressive disorder
FAQs
Is Lexapro bad for your heart?
In this analysis, escitalopram (Lexapro) lengthened the QTc interval by about 8.7 milliseconds compared with placebo. That is a change on a heart tracing, not a heart event. The larger analysis of 139 trials did not find more early major cardiovascular events or non-suicidal deaths with antidepressant use. The effect of escitalopram varied a lot between people, which is why individual risk factors matter when choosing it.
Which antidepressants had the least effect on the QTc interval?
After accounting for personal risk factors, venlafaxine and vortioxetine most often ranked as having the smallest effect on the QTc interval. Amitriptyline and escitalopram most often ranked as having the largest. The study also covered bupropion, duloxetine, fluoxetine, mirtazapine, paroxetine, and trazodone. A ranking is not a safety guarantee, so the best choice still depends on the person taking the drug.
What is a QTc interval?
The QT interval is the time on an ECG between the start of one heartbeat’s electrical signal and the point where the heart has recharged for the next one. Because it naturally shortens as the heart beats faster, doctors correct it for heart rate, and the result is the QTc. This study used a correction method called Fridericia. A longer QTc is one of the signals doctors watch when a drug may affect heart rhythm.
Bottom Line
Among 10 antidepressants tested in double-blind trials, escitalopram and amitriptyline lengthened the QTc heart-rhythm interval compared with placebo, by about 8.7 and 5.3 milliseconds. Yet across 139 trials and 52,398 people, antidepressants were not linked to more early major cardiovascular events or non-suicidal deaths. For most people, that is reassuring. For people with extra heart risk factors, it is a reason to match the drug to the patient.
